Paradigm Biopharmaceuticals (ASX:PAR) Other Current Liabilities: A$3.22 Mil (As of Dec. 2025)


ASX:PAR Paradigm Biopharmaceuticals Ltd ASX:PAR
27 GF Score
Price A$0.18
! 4 Warning Signs
View Full Analysis

What is Paradigm Biopharmaceuticals Other Current Liabilities?

Paradigm Biopharmaceuticals ASX:PAR 27 Other Current Liabilities is A$3.22 Mil as of Dec. 2025. GuruFocus rates ASX:PAR with a GF Score™ of 27/100. The stock has 4 warning signs investors should review.

Paradigm Biopharmaceuticals's other current liabilities for the quarter that ended in Dec. 2025 was A$3.22 Mil.

Paradigm Biopharmaceuticals's quarterly other current liabilities increased from Dec. 2024 (A$0.42 Mil) to Jun. 2025 (A$0.49 Mil) and increased from Jun. 2025 (A$0.49 Mil) to Dec. 2025 (A$3.22 Mil).

Paradigm Biopharmaceuticals's annual other current liabilities declined from Jun. 2023 (A$0.78 Mil) to Jun. 2024 (A$0.42 Mil) but then increased from Jun. 2024 (A$0.42 Mil) to Jun. 2025 (A$0.49 Mil).

Paradigm Biopharmaceuticals Other Current Liabilities Related Terms

Paradigm Biopharmaceuticals Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Paradigm Biopharmaceuticals's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Paradigm Biopharmaceuticals Other Current Liabilities Chart

Paradigm Biopharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.67 0.60 0.78 0.42 0.49

Paradigm Biopharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.82 0.42 0.42 0.49 3.22
ASX:PAR
27GF Score
Paradigm Biopharmaceuticals Ltd ASX:PAR
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Paradigm Biopharmaceuticals Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of A$3.22 Mil mean?
Paradigm Biopharmaceuticals (ASX:PAR) has a Other Current Liabilities of A$3.22 Mil as of Dec. 2025. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Paradigm Biopharmaceuticals.
Is Paradigm Biopharmaceuticals' Other Current Liabilities too high?
Paradigm Biopharmaceuticals' current Other Current Liabilities is A$3.22 Mil. Overall, Paradigm Biopharmaceuticals has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Paradigm Biopharmaceuticals' Other Current Liabilities compare to VRTX and REGN?
Paradigm Biopharmaceuticals' Other Current Liabilities of A$3.22 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Paradigm Biopharmaceuticals. Paradigm Biopharmaceuticals's current Other Current Liabilities is A$3.22 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paradigm Biopharmaceuticals stock overvalued right now?
Paradigm Biopharmaceuticals (ASX:PAR) has a current Other Current Liabilities of A$3.22 Mil. The current Other Current Liabilities is A$3.22 Mil. Paradigm Biopharmaceuticals' overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Paradigm Biopharmaceuticals (ASX:PAR), the current Other Current Liabilities is A$3.22 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Paradigm Biopharmaceuticals Business Description

Other Exchanges PBIGF:USAP86:Germany
Address 500 Collins Street, Level 15, Melbourne, VIC, AUS, 3000
Paradigm Biopharmaceuticals Ltd is a late-stage clinical development company engaged in the research and development of therapeutic products for human use in Australia. The firm is engaged in developing injectable pentosan polysulfate sodium (iPPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The company has registered the trademarks Zilosul and Rhinosul for the commercialization of iPPS.
27GF Score

Get the complete analysis for ASX:PAR

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.18
Price